First Treatment for Children with Lambert-Eaton Myasthenic Syndrome Receives FDA Approval – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Officials with the FDA have approved amifampridine (Ruzurgi, Jacobus) tablets, the first treatment for children with the rare autoimmune disorder Lambert-Eaton myasthenic syndrome (LEMS), according to a press release.
In LEMS, the body’s immune system attacks the neuromuscular junction and disrupts the ability of nerve cells to send signals to muscle cells. The disorder causes weakness and other symptoms in affected patients. Although the prevalence of LEMS in children is not known, the overall prevalence is estimated to be 3 per million individuals worldwide, according to the FDA.